Faegre Drinker Biddle & Reath LLP, a Delaware limited liability partnership | This website contains attorney advertising.
June 24, 2012

Jesse Witten Article Published in Inside Counsel

Washington, D.C., partner Jesse Witten authored an article in Inside Counsel titled, “Abbott’s $1.6 Billion Global Settlement Illustrates Government’s Commitment to Health Care Fraud Enforcement.”

In the article, Jesse explores the details surrounding the government’s $1.6 billion health care fraud settlement with Abbott Laboratories. The case centered around the drug Depakote, which Abbott admitted to promoting as a treatment for schizophrenia and dementia despite the drug only being FDA approved to treat epileptic seizures, bipolar mania and migraine headaches.

Jesse notes the penalties Abbott faces as a result of the criminal guilty plea and subsequent settlement of numerous civil cases, including a $500 million criminal penalty, a $561 million payment to the federal government and an additional $239 million payment to several states. Abbott will also be expected to establish measures for preventing future law violations.

According to Jesse, the Abbott settlement is part of a widespread government crack down on health care fraud. “The Abbott settlement is not the first health care fraud settlement to top $1 billion, and it likely will not be the last,” Jesse warns.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.